Investments

Cornucopian Capital Brings Precision Health to the Masses
Tech & Innovation Cornucopian Capital Brings Precision Health to the Masses

Advances in protein design and enzyme engineering now allow for the rapid modification of bioactive substances, such as decaffeinating beverages in minutes by mimicking the body’s natural metabolic pathways. This breakthrough represents a broader shift toward what Aryeh Ganz and Cornucopian Capital

Karnataka Launches SAMASTA To Streamline Public Health Data
Management & Regulatory Karnataka Launches SAMASTA To Streamline Public Health Data

Alongside its digital transformation, the Karnataka government is allocating over ten crore rupees to expand mental health services across thirty-one underserved taluks in the Kalyana Karnataka region. This strategic investment forms a core component of the broader SAMASTA initiative, which aims to

FDA Backs Syntara’s Phase 2b Myelofibrosis Clinical Trial
Research & Development FDA Backs Syntara’s Phase 2b Myelofibrosis Clinical Trial

Securing a regulatory green light for the Phase 2b trial design ensures that the data generated will meet the rigorous standards required by the United States Food and Drug Administration. This development represents a monumental shift for Syntara Limited, a Sydney-based biotechnology firm that has

Institutional Capital Shifts to Precision Medicine
Management & Regulatory Institutional Capital Shifts to Precision Medicine

The global healthcare landscape is undergoing a monumental transition as the traditional "one-size-fits-all" model gives way to a more sophisticated, precision-based framework. This evolution represents both a significant scientific leap and a massive economic shift that is reshaping how global

How Will the Again-Geno Deal Revolutionize Biomanufacturing?
Management & Regulatory How Will the Again-Geno Deal Revolutionize Biomanufacturing?

The industrial landscape is currently undergoing a seismic shift as the acquisition of Genomatica by the Danish innovator Again creates a formidable powerhouse capable of redefining the boundaries of sustainable chemical production. This merger represents more than just a corporate expansion; it is

Can the CPHI Summit Close the Sustainability Gap in Pharma?
Management & Regulatory Can the CPHI Summit Close the Sustainability Gap in Pharma?

The shift in the pharmaceutical landscape has reached a point where environmental stewardship is no longer an optional component of corporate social responsibility. For decades, the global pharmaceutical sector operated under the assumption that life-saving patient outcomes justified a heavy

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later